Compound sixty has a very significant affinity to MDM2 (Ki < one nM), strong mobile activity, and a very good oral pharmacokinetic profile. Compound sixty is effective at reaching complete and prolonged-Long lasting tumor regression in vivo and it is at this time in phase I clinical trials for cancer https://franciscon776kdw8.blog-gold.com/profile